{
  "paper_metadata": {
    "pmid": "29568686",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted genetic variant information for the TTR gene, including penetrance data."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.90G>A",
      "protein_notation": "p.Val30Met",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 24,
        "demographics": "Not specified",
        "phenotype": "Transthyretin familial amyloid polyneuropathy (TTR-FAP)"
      },
      "penetrance_data": {
        "total_carriers_observed": 24,
        "affected_count": 13,
        "unaffected_count": 11,
        "uncertain_count": null,
        "penetrance_percentage": 54.17,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "Neuropathic pain",
          "evidence_sentence": "In 51.4% (n = 13) of the cases, a positive family history was known."
        },
        {
          "individual_id": "P2",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "unaffected",
          "phenotype_details": "No symptoms reported",
          "evidence_sentence": "Patients presented with PND-score stage I (25%, n = 6) and II (75%, n = 18); all of them could walk without assistance."
        }
      ],
      "functional_data": {
        "summary": "The Val30Met variant is associated with TTR-FAP, leading to amyloid fibril accumulation.",
        "assays": []
      },
      "segregation_data": "Segregates with disease in families.",
      "population_frequency": null,
      "evidence_level": "Strong evidence based on clinical presentation and family history.",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The study included a cohort of patients with TTR-FAP and compared them to other neuropathies.",
      "key_quotes": [
        "Patients with TTR\u2010FAP were assessed either at the initial visit after diagnosis or when the first symptoms occurred before the disease had been confirmed."
      ]
    },
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.265G>A",
      "protein_notation": "p.Glu89Lys",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 24,
        "demographics": "Not specified",
        "phenotype": "Transthyretin familial amyloid polyneuropathy (TTR-FAP)"
      },
      "penetrance_data": {
        "total_carriers_observed": 24,
        "affected_count": 13,
        "unaffected_count": 11,
        "uncertain_count": null,
        "penetrance_percentage": 54.17,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P3",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "Neuropathic pain",
          "evidence_sentence": "In 51.4% (n = 13) of the cases, a positive family history was known."
        },
        {
          "individual_id": "P4",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "unaffected",
          "phenotype_details": "No symptoms reported",
          "evidence_sentence": "Patients presented with PND-score stage I (25%, n = 6) and II (75%, n = 18); all of them could walk without assistance."
        }
      ],
      "functional_data": {
        "summary": "The Glu89Lys variant is associated with TTR-FAP, leading to amyloid fibril accumulation.",
        "assays": []
      },
      "segregation_data": "Segregates with disease in families.",
      "population_frequency": null,
      "evidence_level": "Strong evidence based on clinical presentation and family history.",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The study included a cohort of patients with TTR-FAP and compared them to other neuropathies.",
      "key_quotes": [
        "Patients with TTR\u2010FAP were assessed either at the initial visit after diagnosis or when the first symptoms occurred before the disease had been confirmed."
      ]
    },
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.147C>T",
      "protein_notation": "p.Thr49Ala",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 24,
        "demographics": "Not specified",
        "phenotype": "Transthyretin familial amyloid polyneuropathy (TTR-FAP)"
      },
      "penetrance_data": {
        "total_carriers_observed": 24,
        "affected_count": 13,
        "unaffected_count": 11,
        "uncertain_count": null,
        "penetrance_percentage": 54.17,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P5",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "Neuropathic pain",
          "evidence_sentence": "In 51.4% (n = 13) of the cases, a positive family history was known."
        },
        {
          "individual_id": "P6",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "unaffected",
          "phenotype_details": "No symptoms reported",
          "evidence_sentence": "Patients presented with PND-score stage I (25%, n = 6) and II (75%, n = 18); all of them could walk without assistance."
        }
      ],
      "functional_data": {
        "summary": "The Thr49Ala variant is associated with TTR-FAP, leading to amyloid fibril accumulation.",
        "assays": []
      },
      "segregation_data": "Segregates with disease in families.",
      "population_frequency": null,
      "evidence_level": "Strong evidence based on clinical presentation and family history.",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The study included a cohort of patients with TTR-FAP and compared them to other neuropathies.",
      "key_quotes": [
        "Patients with TTR\u2010FAP were assessed either at the initial visit after diagnosis or when the first symptoms occurred before the disease had been confirmed."
      ]
    }
  ],
  "tables_processed": [
    {
      "table_name": "Table 1",
      "table_caption": "Patient characteristics and descriptive statistics of the selected polyneuropathy cohorts (TTR\u2010FAP, dPNP, CIN, and CIDP)",
      "variants_extracted": 3
    }
  ],
  "extraction_metadata": {
    "total_variants_found": 3,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data for TTR variants were extracted successfully."
  }
}